MetaADEDB 2.0 @ LMMD
Polymyxin B
(WQVJHHACXVLGBL-BPJDFBQWSA-N)
Structure
SMILES
NCC[C@@H](C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)Cc1ccccc1)CC(C)C)CCN)[C@H](O)C)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)CCCCC(CC)C)CCN
Type(s)
Approved; Vet_approved
ATC code(s)
A07AA05; J01XB02; S01AA18; S02AA11; S03AA03
Molecular Formula:
C56H98N16O13
Molecular Weight:
1203.480
Log P:
2.1219
Hydrogen Bond Acceptor:
29
Hydrogen Bond Donor:
18
TPSA:
490.66
CAS Number(s):
1404-26-8
Synonym(s)
1.
Polymyxin B
2.
Aerosporin
3.
Polymyxin B Sulfate
External Link(s)
MeSHD011112
PubChem Compound49800004
BindingDB50410807
CHEMBLCHEMBL1201283
DrugBankDB00781
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Blood creatinine increasedFAERS: 2US FAERS
2Acute kidney injuryFAERS: 14292201
24189134
26385100		CTD
US FAERS
3Application site rashFAERS: 1US FAERS
4Blood urea increasedFAERS: 1US FAERS
5DizzinessFAERS: 1US FAERS
6HypersensitivityFAERS: 1US FAERS
7HypotensionFAERS: 1US FAERS
8Oropharyngeal discomfortFAERS: 1US FAERS
9OverdoseFAERS: 1US FAERS
10Product expiration date issueFAERS: 1US FAERS
11ScabFAERS: 1US FAERS
12TachycardiaFAERS: 1US FAERS
13Chemical and Drug Induced Liver Injury26385100CTD
14Cystitis6245359CTD
15Deafness646445CTD
16Eczema31132327CTD
17Eosinophilia4292201CTD
18Exanthema31132327CTD
19Extravasation of Diagnostic and Therapeutic Materials31132327CTD
20Glomerulonephritis12845235CTD
21Glycosuria, Renal4292201CTD
22Hemorrhage6245359CTD
23Hypocalcemia646445CTD
24Hypokalemia646445CTD
25Inflammation26385100CTD
26Nephritis, Interstitial4292201CTD
27Oliguria4292201CTD
28Tetany646445CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.